Søby S, Prestwich R, Gyldenkerne N, Maare C, Lonkvist CK, Andersen M, et al. Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study. AO [Internet]. 2025 Sep. 21 [cited 2026 Jul. 13];64:1269-75. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/44327